產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-POU6F2抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢(xún)訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-POU6F2抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-POU6F2
Cat. Number:
Anti-POU6F2抗體KL-6084R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene encodes a member of the POU protein family characterized by the presence of a bipartite DNA binding domain, consisting of a POU-specific domain and a homeodomain, separated by a variable polylinker. The DNAAnti-POU6F2抗體 binding domain may bind to DNA as monomers or as homo- and/or heterodimers, in a sequence-specific manner. The POU family members are transcriptional regulators, many of which are known to control cell type-specific differentiation pathways. This gene is a tumor suppressor involved in Wilms tumor (WT) predisposition. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
Also known as:
POU class 6 homeobox 2; POUAnti-POU6F2抗體 domain class 6 transcription factor 2; Retina derived POU domain factor 1; RPF 1; RPF1; Wilms tumor suppressor locus; WT 5; WT5; WTSL; PO6F2_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Anti-POU6F2抗體Chicken, Dog, Pig, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human POU6F2.
●
Predicted Molecular Weight: 73kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-POU6F2抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-POU6F2抗體
Optimal working dilutions must be determined by the end user.
